Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.
Advertisement

Related Content

Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Sanofi Avoids Patent Cliff For Now, Returns to Growing Sales And Profits In Third Quarter
Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Prostate Cancer Market Snapshot: More Than Provenge
A Chock-Full Pipeline For Prostate Cancer Drugs
With Jevtana Approved For Advanced Prostate Cancer, Sanofi Could See Expansion To First-Line Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS072172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel